Who Owns Amylyx Pharmaceuticals Stock?
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 97.87%
- Institutions (% of float)
- 105.07%
- Held by insiders
- 6.85%
- Institutional holders
- 307
- Institutions 93.1%
- Insiders 6.9%
- Public and other 0.0%
Who owns Amylyx Pharmaceuticals stock?
Institutional investors own about 97.9% of Amylyx Pharmaceuticals's shares, spread across 307 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 6.85% of AMLX.
The largest institutional holders are FMR, LLC (15.51%), Blackrock Inc. (8.06%) and Perceptive Advisors Llc (6.48%). Together, the top 10 institutions control 56.7% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their AMLX positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of AMLX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 19.95M | 15.51% | +19.2% |
| Blackrock Inc. | 10.37M | 8.06% | +17.5% |
| Perceptive Advisors Llc | 8.33M | 6.48% | +0.6% |
| TCG Crossover Management, LLC | 6.24M | 4.86% | 0.0% |
| Commodore Capital Lp | 5.65M | 4.39% | 0.0% |
| Jupiter Topco LLC | 5.24M | 4.07% | +100.0% |
| Vanguard Capital Management LLC | 5.08M | 3.95% | +20.2% |
| Saturn V Capital Management LP | 4.62M | 3.60% | +6.3% |
| Franklin Templeton, Inc. | 3.93M | 3.06% | +33.3% |
| JPMORGAN CHASE & CO | 3.43M | 2.67% | +84.3% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of AMLX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15M | 2.45% |
| iShares Trust-iShares Russell 2000 ETF | 2.69M | 2.10% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 2.43M | 1.89% |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.12M | 1.65% |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.70M | 1.32% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.60M | 1.25% |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.60M | 1.24% |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 1.48M | 1.15% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.32M | 1.03% |
| Fidelity Securities Fund-Fidelity Series Small Cap Opportunities Fund | 1.18M | 0.92% |
Frequently asked questions
Who is the largest shareholder of Amylyx Pharmaceuticals?
FMR, LLC is the largest institutional shareholder of AMLX, owning 15.51% of shares outstanding (19.95M shares) as of its latest 13F filing.
What percentage of Amylyx Pharmaceuticals is owned by institutions?
Institutions own about 97.9% of AMLX shares and 105.1% of the public float.
How much of Amylyx Pharmaceuticals do insiders own?
Insiders, such as officers and directors, own about 6.85% of AMLX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.